Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

Benzinga · 2d ago
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.